Focus luglio-agosto 2015
Italiano
Missing a dose of Hydrochlorothiazide could result in uncontrolled blood pressure or swelling caused by excess fluid (edema).
The device could be accessed remotely through a hospital’s network. This could allow an unauthorized user to control the device and change the dosage the pump delivers, which could lead to over- or under-infusion of critical patient therapies.
Leaking containers, particulate matter and missing port protectors could result in contamination of the solution. If not detected, this could lead to a bloodstream infection or other serious adverse health consequences.
L'Agenzia Italiana del Farmaco comunica nuove e importanti aggiornamenti sul rischio di perforazione uterina.
FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).
Administration of an intravenous product with particulate matter has the potential to result in inflammation, allergic reactions, or blockage of blood vessels, leading to tissue death, which may be life-threatening if vital organs are affected.
Health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.
If there is contamination in products intended to be sterile, patients are at risk of serious infections which may be life threatening.
L’Agenzia Europea dei Medicinali (EMA) ha avviato una revisione su InductOs,
un impianto utilizzato in pazienti con problemi ai dischi
intervertebrali e fratture alle gambe a seguito di non conformità
rilevate durante l’ispezione di un sito di produzione di un componente
del medicinale.
80.211.154.110